Osteomyelitis is an infectious process in bone occasionally leading to bone destruction. Traditionally a two-stage operation is performed using PMMA + antibiotic beads or a spacer. In the second operation the void filler is removed and the defect is filled with autologous bone.

Bioactive glass (BAG) S53P4 is an antibacterial biodegradable bone substitute. This feature is based on an increase in pH and the osmotic pressure around the BAG, a phenomenon which has been shown to kill both planktonic bacteria and bacteria in biofilm in-vitro.

We analyzed retrospectively our early results of osteomyelitis patients treated with BAG from the patient's clinical history

The diagnosis was stated in addition to bacterial samples by MRI, CT and plain radiographs or by a combination of these. Between 2007–2013 we applied BAG as a void-filler in 20 cases (15 male and 5 female) of osteomyelitis in the lower (19) or the upper (1) limb in one-stage procedure. The patients had been suffering from symptoms of osteomyelitis a mean 3,5 months (0,25–24,00) and had a history of mean 3,5 (1–11) earlier operations.

Osteomyelitis was estimated to be healed when the enclosed systemic antibiotic treatment and clinical controls were carried out and the patient didn't have symptoms of a persisting disease.

The average postoperative follow up was 7,8 (3,0–59,0) months. Fifteen (75%) of the patients healed. One patient run out of controls, but was symptom free during his last visit. In four cases we had to remove the bioactive glass because of continuous secretion. In three cases the debridement was incomplete and one had a poor soft tissue cover and a candida infection. Adjuvant systemic antibiotic treatment was prescribed postoperatively 7,3 (4–19) weeks.

Bioactive glass is an effective void filling material in the treatment of osteomyelitis. Proper debridement and a soft tissue cover should be performed.

Main reason for that the five patients did not heal is, that this procedure is new and we were looking for the right indications and techniques.

Introduction: We have shown that an IL6 haplotype (GGGA) associates with intervertebral disc disease (IDD) characterized by sciatica. However, its prognostic value for IDD is not known.

Materials and methods: DNA from 153 sciatica patients, who participated in a randomized controlled trial of periradicular infiltration, was analyzed for IL6 variations: c.1–597G> A, c.1–572G> C, c.1–174G> C, and c.486T> A (Genebank #NM_000600.1). Patients recorded back and leg pain intensity and duration (number of days with pain), Oswestry disability, and back-related sick leaves. Repeated measures ANCOVA with adjustment for age, gender and physical work load was used. Square root transformations of outcome data at one, two and three years after the intervention were used for skewed variables.

Results: The prevalence of the GGGA haplotype was 9% (14/153). Data was available from 10 (sick leaves) to 13 (VAS) subjects with and from 107 to 124 subjects without the haplotype. The groups did not differ with respect to pain intensities, or disability. Days with back and leg pain and sick leaves were significantly higher among subjects with the IL6 haplotype (p=0.024, 0.002 and 0.022, respectively). An interaction of the IL6 haplotype and physical work load was significant for duration of back and leg pain and sick leaves (p=0.010, 0.004 and 0.018, respectively).

Discussion: This is the first observation of any prognostic genotype among sciatica patients. The IL6 haplotype GGGA predicted the number of days with back or leg pain, and sickness absence. Subjects with the IL6 haplotype may be more vulnerable when exposed to physically demanding job.